Disclosures for "Tracking the immune response to SARS-CoV-2 mRNA booster vaccination in an open-label multicenter study in participants with relapsing multiple sclerosis treated with ofatumumab s.c. (KYRIOS clinical trial)")
-
Prof. Bopp has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Prof. Bopp has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Prof. Bopp has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva. Prof. Bopp has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Prof. Bopp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pathios Therapeutics. The institution of Prof. Bopp has received research support from DFG (German Research Foundation). The institution of Prof. Bopp has received research support from BMBF. Prof. Bopp has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Groth has received personal compensation for serving as an employee of Novartis Pharma GmbH.
-
Dr. Winkelmann has received personal compensation for serving as an employee of Novartis Pharma GmbH.
-
Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BMS Celgene. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Novartis. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Ziemssen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for BMS Celgene. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TEVA. The institution of Dr. Ziemssen has received research support from Biogen. The institution of Dr. Ziemssen has received research support from Novartis. The institution of Dr. Ziemssen has received research support from Merck. The institution of Dr. Ziemssen has received research support from Sanofi. The institution of Dr. Ziemssen has received research support from Celgene.